New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

Shares of Summit Therapeutics (SMMT) jumped as much as 5% on Wednesday before paring some gains after the company released ...

Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

Alveltamig is a trispecific T-cell engager, enhancing immune response by linking T cells to cancer cells with three binding arms. The trial addresses treatment challenges for small cell lung cancer ...

Researchers found that mRNA cancer vaccines can recruit an unexpected immune cell to launch powerful tumor-fighting responses, overturning a long-held assumption about how the vaccines work. The ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment. Targeting ...